GLP-1 Reduces Heavy Drinking in Clinical Trial
Weekly semaglutide with CBT significantly reduced heavy drinking in alcohol use disorder & obesity patients, per a clinical trial.
04 May 2026
Weekly semaglutide with CBT significantly reduced heavy drinking in alcohol use disorder & obesity patients, per a clinical trial.
GLP-1 study reports semaglutide preserved lean mass better than tirzepatide, with a 2% higher lean mass loss on tirzepatide over 12 months.
